Copy of Live now banner

The Pre-Conference Workshops are now live!

Don’t worry, there is still time to secure your pass

REGISTER HERE

Patient Enrollment Innovative Trends Using a Liquid Biopsy

Wednesday February 9 | 12.30pm - 3.30pm PT |
3.30pm - 6.30pm ET | Workshop Taking Place Digitally

Note: If you are already signed up to the main conference, you can upgrade your ticket by using your details & choosing  Guardant Health Workshop - Patient Enrollment Innovative Trends Using a Liquid Biopsy.

Providing you with an outlook on the clinical disruption in CRC, Lung and Breast Cancer influenced by MRD monitoring, join this Guardant Health workshop to discuss the latest MRD trends showcased by innovative use cases in early-stage disease.

Leveraging latest technological progress in focal amplification detection, the workshop will also delve deep in the uncovering of copy number alterations to enroll patients in relevant biomarker-informed late-stage cancer trials.

 

What will you discuss?

    • Unmet clinical and diagnostic needs in the adjuvant and neoadjuvant settings, as well as the potential of LBx to provide a solution
    • Targeted amplications (e.g. ERBB2, MET) and the corresponding biomarker-informed treatments
    • Underlying technological (sensitivity vs. specificity in MRD, focal amplification vs. aneuploidy) and clinical challenges for a prospective trial roll-out and LBx considerations

Expert Speakers:

David Chun Cheong Tsui

Senior Thoracic Oncology Fellow

Yoshiaki Nakamura

Staff Physician in Translational Research Support Section, Department of Gastrointestinal Oncology

David Gadara

Director of Thoracic Oncology

Pedram Razavi

Medical Oncologist

Memorial Sloan Kettering Cancer Center

medical-campus
national-east
1280px-UC_Davis_Medical_Center_wordmark.svg_
Memorial-Sloan

Kimberly Banks

VP of Medical Affairs

Guardant Health

Thereasa Rich

Medical Science Liaison

Guardant Health

Justin Odegaard

Vice President, Clinical Development

Guardant Health

Sara Wienke

Medical Science Liaison

Guardant Health

Workshop Agenda: Patient Enrollment Innovative Trends Using a Liquid Biopsy

Wednesday February 9, 2022 | 12.30pm – 3.30pm PT

12:30 pm Hanson Wade & Guardant Health Opening Remarks

Clinical Trends Using MRD in Bladder, Lung & Breast

Synopsis

The objective of this session is to review and discuss the latest trends in Bladder, Lung and Breast oncology trials and innovative MRD use cases to solve outstanding clinical challenges in early-stage disease. Our expert speaker and panelists will discuss unmet clinical and diagnostic needs in the adjuvant and neoadjuvant settings, as well as the potential of LBx to provide a solution.

12:35 pm Presentation

  • David Gandara Professor, Director, Thoracic Oncology Program; Chief Medical Officer, UC Davis Comprehensive Cancer Center; International Society for Liquid Biopsy

1:00 pm Panel Discussion

  • David Gandara Professor, Director, Thoracic Oncology Program; Chief Medical Officer, UC Davis Comprehensive Cancer Center; International Society for Liquid Biopsy
  • Pedram Razavi Medical Oncologist, Memorial Sloan Kettering Cancer Center
  • Thereasa Rich Medical Science Liaison, Guardant Health
  • Petros Grivas Director of Colon Cancer Research, Weill Cornell Medicine

Guardant Health Clinical Roll-out of MRD Monitoring

1:35 pm Presentation

2:00 pm Break

Copy Number Alterations: Clinical Unmet Needs & LBx Impact

Synopsis

This session will delve into the specific challenges that late-stage cancer patients are facing with emerging copy number alterations and in the innovative diagnostic solutions to inform clinical decisions. For instance, our panel will discuss mechanisms of resistance (e.g. CCNE1, ERBB2, MET) as well as the corresponding biomarkerinformed treatments. The panelists will also touch on the underlying technological (focal amplification vs. aneuploidy) and clinical challenges for a prospective trial roll-out and LBx considerations.

2:05 pm Presentation

2:30 pm Presentation

  • Yoshiaki Nakamura Staff Physician in Translational Research Support Section, Department of Gastrointestinal Oncology,

2:55 pm Panel Discussion

3:25 pm Closing Remarks

3:30 pm End of Guardant Health Workshop

ABOUT GUARDANT HEALTH

Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets, and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ test for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.

www.guardanthealth.com